In summary, patients who developed CM-IRIS exhibited aberrant CD4+ T cell responses during the primary CM episode as demonstrated by their poor mitogenic and GXM-specific IL-2 responses. This evidence concerns the gene IL2 and cutaneous mastocytosis.